Industry Detail

Neuropathic Corneal Pain (NCP) Market Outline:

The 9MM Muscle Neuropathic Corneal Pain (NCP) Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.

The disease is caused by the impairement of corneal nerves. Disease remains ill-defined also named with few other terms such as corneal neuralgia, corneal allodynia and many more. Neuropathic Corneal Pain (NCP) characterized by severe pain, hyperalgesia, burning, and photoallodynia and significantly affecting quality of patient life. Sometime the disease may have overlapping symptoms with dry eye disease. These patients do not respond to the conventional dry eye disease treatment

Cases of Neuropathic Corneal Pain (NCP) very often occurs, following ocular trauma or surgery, herpes simplex keratitis or herpes zoster ophthalmicus. Disease faces several diagnosis challenges, while distingushing it from dry eye disease. 

Neuropathic Corneal Pain (NCP), Disease Burden Analysis:

The prevalence of NCP is estimated to be around 6.5–9.0%, it may vary depending on region and country.

Treatment Landscape: 

Treating NCP patient is highly challenging, there is still lack of topical targeted treatment to alleviate ocular pain

Report has examined the how many and what type of cases refer to which type of therapy based on experts opinion analysis.

 Report also examined Approaches for Management

• First-line of therapy
• Second-line of therapy

Recent developments in the market: OKYO Pharma Receives FDA Approval of IND for OK-101

Several pipeline assests are under investigation, and expected to witness the market during the forecast period. 

Report also provided promising therapy assessment including drugs, existing therapies and upcoming therapy

Few Report Insights:

• CSP Analytics Solutions provided the clinical mapping of key pipeline molecules
• CSP Analytics Solutions also analyzed the unmet need and patients treatment gaps in the market. 
• Neuropathic Corneal Pain (NCP) market is struggling to get effective treatment

The 9MM Neuropathic Corneal Pain (NCP) Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during estimated year i.e. 2023 and expected to grow at a significant CAGR XX% over the projected period. And by 2033, the market is expected to touch USD XX Million.

Market Segmentation Analysis by:

• By Line of Therapy:
  • First-Line Therapy
  • Second-Line Therapy
• By Therapy Type:
  • Monotherapy
  • Combination Therapy
• By Gender:
  • Male
  • Female
• By Route of Administration:
  • Oral
  • Topical
  • Injectable

Market Dynamics: Explored in the report

• Untreated Prevalent Pool of Neuropathic Corneal Pain (NCP)
• Growing Clinical Trial Activities
• Lack of FDA approved Therapy
• Huge Market Unmet Need
• Rising drug Penetration in Neuropathic Corneal Pain (NCP) Segment

Market Challenges: Explored in the report

• Lack of Efficacious Treatment Options
• Difficulty in diagnosis
• Underdiagnoses in Emerging Market

Regional Outlook: 

Report has fragmented the total market into five regions such as US, 5-Europe, China, Japan, India and RoW (Rest of world). 

Each mapped region has been examined at granular level based on below parameters:

• United States Neuropathic Corneal Pain (NCP) Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)
• 5-Europe Neuropathic Corneal Pain (NCP) Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)
  • By Country
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
• China Neuropathic Corneal Pain (NCP) Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)
• India Neuropathic Corneal Pain (NCP) Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)
• Japan Neuropathic Corneal Pain (NCP) Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)
• Rest of the World Neuropathic Corneal Pain (NCP) Drug Treatment Market
  • Market Size and Forecast Model 2023-2033
  • Disease Classification
  • Current Treatment Approaches
  • Key Opinion Leader (KOL) Views
  • Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
  • Diagnosis and Treatment Guidelines
  • Drug Share Analysis (%)
  • Current Treatment Landscape and Upcoming therapy Assessment
  • Market Unmet Need Analysis
  • Key Players in the Market and their Market share (%)

Competitive Landscape (Existing and Pipeline Players): Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.

Companies Profile:

• Shire (a subsidiary of Takeda Pharmaceutical Company Limited)
• Novartis AG
• Alcon (a division of Novartis AG)
• Allergan (acquired by AbbVie)
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals, Inc.
• Neuroptika, Inc.
• Ocular Therapeutix, Inc.
• Kala Pharmaceuticals, Inc.
• Eyevance Pharmaceuticals
• OKYO Pharma
• Others

Reason to buy this report: 

• Fostering Understanding on Neuropathic Corneal Pain (NCP) Drug Treatment Market
• In Order to Understand the Market Potential
• Opportunity Analysis (exist in the market for players)
• Clinical Developments in the market
• To Know Current and Future Market Trends
• Key Players and their Key Strategic Move

Excel Model: